OGN - Organon & Co. Stock Price, Fair Value and News

21.65USD+0.30 (+1.41%)Market Closed

Market Summary

USD21.65+0.30

Market Closed

1.41%

OGN Stock Price

View Fullscreen

OGN RSI Chart

OGN Valuation

Market Cap

5.6B

Price/Earnings (Trailing)

5.32

Price/Sales (Trailing)

0.88

EV/EBITDA

10.38

Price/Free Cashflow

10.92

OGN Price/Sales (Trailing)

OGN Profitability

EBT Margin

10.62%

Return on Equity

2.2K%

Return on Assets

8.8%

Free Cashflow Yield

9.16%

OGN Fundamentals

OGN Revenue

Revenue (TTM)

6.3B

Rev. Growth (Yr)

5.46%

Rev. Growth (Qtr)

1.5%

OGN Earnings

Earnings (TTM)

1.0B

Earnings Growth (Yr)

13.56%

Earnings Growth (Qtr)

-63.19%

Breaking Down OGN Revenue

Last 7 days

6.3%

Last 30 days

22.3%

Last 90 days

16.3%

Trailing 12 Months

6.1%

How does OGN drawdown profile look like?

OGN Financial Health

Current Ratio

1.65

Debt/Equity

181.35

Debt/Cashflow

0.09

OGN Investor Care

Dividend Yield

5.17%

Dividend/Share (TTM)

1.12

Shares Dilution (1Y)

0.83%

Diluted EPS (TTM)

4.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	6.3B	0	0	0
2023	6.1B	6.2B	6.2B	6.3B
2022	6.4B	6.4B	6.3B	6.2B
2021	6.3B	6.3B	6.3B	6.3B
2020	7.5B	7.2B	6.8B	6.5B
2019	0	0	0	7.8B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Organon & Co.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 04, 2024	weaver kirke	sold (taxes)	-6,981	19.61	-356	gen. counsel & corp. secy.
May 04, 2024	ali kevin	sold (taxes)	-240,340	19.61	-12,256	chief executive officer
May 04, 2024	morrissey joseph t. jr.	acquired	-	-	3,604	head of manufacturing
May 04, 2024	falcione aaron	sold (taxes)	-18,600	19.6	-949	chief human resources officer
May 04, 2024	fiedler susanne	acquired	-	-	4,989	chief commercial officer
May 04, 2024	morrissey joseph t. jr.	sold (taxes)	-30,748	19.61	-1,568	head of manufacturing
May 04, 2024	stahler rachel a	acquired	-	-	3,049	chief information officer
May 04, 2024	fiedler susanne	sold (taxes)	-31,160	19.61	-1,589	chief commercial officer
May 04, 2024	walsh matthew m	sold (taxes)	-80,263	19.61	-4,093	chief financial officer
May 04, 2024	walsh matthew m	acquired	-	-	8,310	chief financial officer

Which funds bought or sold OGN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	new	-	8,795,000	8,795,000	0.01%
May 15, 2024	Laird Norton Wetherby Wealth Management, LLC	new	-	240,734	240,734	0.01%
May 15, 2024	AMUNDI	reduced	-1.15	173,390	2,078,760	-%
May 15, 2024	Point72 Asset Management, L.P.	sold off	-100	-45,982,500	-	-%
May 15, 2024	Royal Bank of Canada	reduced	-12.25	433,000	3,435,000	-%
May 15, 2024	SYSTEMATIC FINANCIAL MANAGEMENT LP	unchanged	-	3,197	13,724	-%
May 15, 2024	UNITED SERVICES AUTOMOBILE ASSOCIATION	added	23.85	142,868	375,304	0.01%
May 15, 2024	ARISTEIA CAPITAL, L.L.C.	new	-	246,355	246,355	-%
May 15, 2024	BOKF, NA	reduced	-17.27	462	7,974	-%
May 15, 2024	Magnetar Financial LLC	reduced	-17.11	2,590,310	34,680,000	0.78%

Are Funds Buying or Selling OGN?

Are funds buying OGN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OGN

No. of Funds

Unveiling Organon & Co.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	11.97%	30,596,708	SC 13G/A
Feb 05, 2024	mawer investment management ltd.	0.00%	0	SC 13G/A
Jan 25, 2024	state street corp	3.72%	9,506,568	SC 13G/A
Jan 23, 2024	blackrock inc.	13.1%	33,523,293	SC 13G/A
Nov 07, 2023	blackrock inc.	12.7%	32,427,810	SC 13G/A
Feb 13, 2023	mawer investment management ltd.	5.39%	13,721,690	SC 13G
Feb 10, 2023	state street corp	5.06%	12,863,077	SC 13G
Feb 09, 2023	vanguard group inc	12.37%	31,471,695	SC 13G/A
Feb 07, 2023	blackrock inc.	6.4%	16,387,716	SC 13G/A
Feb 04, 2022	blackrock inc.	6.7%	16,900,502	SC 13G

Recent SEC filings of Organon & Co.

View All Filings

Date Filed	Form Type	Document
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 03, 2024	10-Q	Quarterly Report

Peers (Alternatives to Organon & Co.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	367.4B	85.6B	3.44%	-4.19%	9.55	4.29	5.68%	202.39%
MRK	333.7B	61.4B	4.40%	13.49%	144.7	5.43	6.11%	-82.30%
AMGN	171.1B	29.5B	20.16%	41.33%	45.48	5.8	12.76%	-52.47%
PFE	163.3B	57.8B	11.19%	-22.16%	130.24	2.82	76.51%	-86.81%
GILD	83.5B	27.4B	-1.12%	-14.47%	172.26	3.04	1.51%	-91.32%
TEVA	19.0B	16.0B	26.76%	106.27%	-38.41	1.19	7.23%	71.10%
MID-CAP
PRGO	4.1B	4.6B	0.30%	-7.98%	-535.01	0.9	-0.06%	94.55%
ALKS	4.1B	1.7B	0.50%	-22.18%	9.4	2.37	54.01%	364.56%
BHC	2.6B	9.0B	-17.96%	17.61%	-5.71	0.29	10.01%	-27.45%
AMPH	2.1B	676.2M	4.10%	-1.14%	13.42	3.07	30.38%	66.04%
SMALL-CAP
TLRY	1.6B	743.2M	15.73%	-12.34%	-4.53	2.15	24.65%	80.36%
TXMD	24.2M	1.3M	7.69%	-52.27%	-3.27	18.6	-98.14%	-104.71%
ACRX	20.6M	89.6M	17.48%	61.29%	-1.45	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-91.38%	-0.32	0.12	66.16%	61.83%
ACOR	472.0K	115.7M	-50.00%	-97.38%	0	0	-2.22%	-352.48%

Organon & Co. News

Latest updates

Organon & Co. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																		(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	1.5%	1,622	1,598	1,519	1,608	1,538	1,485	1,537	1,585	1,567	1,603	1,600	1,595	1,506	1,613	1,613	1,526	1,780	-
S&GA Expenses	-8.1%	431	469	538	451	435	470	440	423	371	482	388	416	382	434	321	284	317	-
R&D Expenses	-	-	-	-	-	-	-	-	-	96.00	-76.50	111	10.00	67.00	2.00	54.00	51.00	45.00	-
EBITDA Margin	-1.3%	0.21*	0.21*	0.21*	0.24*	0.24*	0.27*	0.28*	0.29*	0.31*	0.30*	0.30*	-	-	-	-	-	-	-
Interest Expenses	1.6%	131	129	134	132	132	119	108	98.00	97.00	98.00	98.00	62.00	-	-	-	-	-	-
Income Taxes	107.9%	35.00	-442	22.00	12.00	58.00	3.00	55.00	53.00	94.00	34.00	66.00	6.00	72.00	149	121	116	110	-
Earnings Before Taxes	126.9%	236	104	80.00	254	235	111	282	287	442	236	389	437	467	525	681	702	844	-
EBT Margin	-1.2%	0.11*	0.11*	0.11*	0.14*	0.15*	0.18*	0.20*	0.21*	0.24*	0.24*	0.29*	-	-	-	-	-	-	-
Net Income	-63.2%	201	546	58.00	242	177	108	227	234	348	202	323	427	399	368	547	542	703	-
Net Income Margin	1.0%	0.16*	0.16*	0.10*	0.12*	0.12*	0.15*	0.16*	0.17*	0.20*	0.21*	0.24*	-	-	-	-	-	-	-
Free Cashflow	-90.6%	30.00	318	206	-44.00	68.00	204	262	106	90.00	-12.00	332	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-1.4%	11,891	12,058	11,012	10,979	10,763	10,955	10,437	10,614	10,597	10,681	11,335	10,908	9,642	10,109
Current Assets	-6.9%	4,196	4,508	4,050	3,958	3,780	3,931	3,592	3,774	3,719	3,760	4,329	3,911	2,977	3,567
Cash Equivalents	-17.0%	575	693	414	326	459	706	499	545	694	737	1,008	730	141	12.00
Inventory	-4.0%	1,263	1,315	1,186	1,199	1,121	1,003	879	950	946	915	918	871	924	913
Net PPE	-0.3%	1,180	1,183	1,096	1,110	1,055	1,018	906	952	970	973	967	976	986	984
Goodwill	0%	4,603	4,603	4,603	4,603	4,603	4,603	4,603	4,603	4,603	4,603	4,603	4,603	4,603	4,603
Liabilities	-2.3%	11,843	12,128	11,601	11,534	-	11,847	-	-	-	-	-	-	-	-
Current Liabilities	-12.8%	2,545	2,918	2,491	2,387	2,346	2,512	2,328	2,396	2,306	2,597	3,129	2,975	2,875	2,673
Long Term Debt	-0.5%	8,705	8,751	8,646	8,722	8,703	8,905	8,691	8,884	9,085	9,125	9,259	9,309	-	-
LT Debt, Current	0%	9.00	9.00	8.00	8.00	8.00	8.00	8.00	9.00	9.00	9.00	39.00	39.00	-	-
LT Debt, Non Current	-100.0%	-	8,751	8,646	8,722	8,703	8,905	8,691	8,884	9,085	9,125	9,259	9,309	-	-
Shareholder's Equity	168.6%	48.00	-70.00	-	-	-737	-892	-	-	-	-	-	-	4,722	5,486
Retained Earnings	29.3%	573	443	-16.00	-25.00	-206	-331	-383	-551	-724	-998	-1,128	-1,473	-	-
Additional Paid-In Capital	96.0%	49.00	25.00	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	0.1%	256	256	256	256	254	254	254	254	254	254	254	254	-	-
Float	-	-	-	-	5,300	-	-	-	8,600	-	-	-	7,670	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																		(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	-80.9%	76.00	397	261	27.00	114	267	317	151	123	47.00	368	445	1,300	484	320	733	747	-
Share Based Compensation	-3.7%	26.00	27.00	27.00	25.00	22.00	23.00	18.00	19.00	15.00	15.00	15.00	18.00	11.00	8.00	11.00	11.00	10.00	-
Cashflow From Investing	-18.5%	-96.00	-81.00	-55.00	-70.00	-54.00	-61.00	-213	-83.00	-63.00	-133	-61.00	-249	-38.00	-119	-45.00	-47.00	-39.00	-
Cashflow From Financing	3.9%	-74.00	-77.00	-78.00	-88.00	-326	-82.00	-77.00	-183	-91.00	-187	-18.00	345	-1,117	-353	-275	-686	-708	-
Dividend Payments	-4.1%	70.00	73.00	74.00	74.00	73.00	73.00	74.00	72.00	71.00	71.00	74.00	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

OGN Income Statement

2024-03-31

Condensed Consolidated Statements of Income - USD ($) shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues	$ 1,622	$ 1,538
Costs, Expenses and Other
Cost of sales	665	580
Selling, general and administrative	431	435
Research and development	112	129
Acquired in-process research and development and milestones	15	8
Restructuring costs	23	4
Interest expense	131	132
Exchange losses	6	9
Other expense, net	3	6
Total, costs expenses and other	1,386	1,303
Income Before Income Taxes	236	235
Taxes on income	35	58
Net Income	$ 201	$ 177
Earnings per Share:
Basic (in dollars per share)	$ 0.78	$ 0.70
Diluted (in dollars per share)	$ 0.78	$ 0.69
Weighted Average Shares Outstanding:
Basic (in shares)	255,695	254,392
Diluted (in shares)	258,362	256,170

OGN Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 575	$ 693
Accounts receivable (net of allowance for doubtful accounts of $11 in 2024 and $9 in 2023)	1,547	1,744
Inventories (excludes inventories of $101 in 2024 and $110 in 2023 classified in Other assets)	1,263	1,315
Other current assets	811	756
Total Current Assets	4,196	4,508
Property, plant and equipment, net	1,180	1,183
Goodwill	4,603	4,603
Intangibles, net	718	533
Other assets	1,194	1,231
Total Assets	11,891	12,058
Current Liabilities:
Current portion of long-term debt	9	9
Trade accounts payable	955	1,314
Accrued and other current liabilities	1,385	1,389
Income taxes payable	196	206
Total Current Liabilities	2,545	2,918
Long-term debt	8,705	8,751
Deferred income taxes	44	47
Other noncurrent liabilities	549	412
Total Liabilities	11,843	12,128
Contingencies (Note 15)
Organon & Co. Stockholders’ Equity (Deficit):
Common stock, $0.01 par value Authorized - 500,000 Issued and outstanding - 255,847 in 2024 and 255,626 in 2023	3	3
Additional paid-in capital	49	25
Retained earnings	573	443
Accumulated other comprehensive loss	(577)	(541)
Total Stockholders’ Equity (Deficit)	48	(70)
Total Liabilities and Stockholders’ Equity (Deficit)	$ 11,891	$ 12,058

About Organon & Co.

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive; Nuvaring, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

CEO	Mr. Kevin Ali
WEBSITE	organon.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	10000

Organon & Co. Frequently Asked Questions

What is the ticker symbol for Organon & Co.? What does OGN stand for in stocks?

OGN is the stock ticker symbol of Organon & Co.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Organon & Co. (OGN)?

As of Wed May 15 2024, market cap of Organon & Co. is 5.57 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OGN stock?

You can check OGN's fair value in chart for subscribers.

What is the fair value of OGN stock?

You can check OGN's fair value in chart for subscribers. The fair value of Organon & Co. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Organon & Co. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Organon & Co. a good stock to buy?

The fair value guage provides a quick view whether OGN is over valued or under valued. Whether Organon & Co. is cheap or expensive depends on the assumptions which impact Organon & Co.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OGN.

What is Organon & Co.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 15 2024, OGN's PE ratio (Price to Earnings) is 5.32 and Price to Sales (PS) ratio is 0.88. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OGN PE ratio will change depending on the future growth rate expectations of investors.